In a cohort of 743 patients with de novo DLBCL treated with standard rituximab–CHOP therapy, the expression of CXCR4 is associated with the male gender, tumor volume, ABC subtype, and high Ki-67 index, Myc, and Bcl-2 or p53 [138]. This evidence concerns the gene CXCR4 and neoplasm.